<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631368</url>
  </required_header>
  <id_info>
    <org_study_id>LSSC-BOTOXSCAR-2018</org_study_id>
    <nct_id>NCT03631368</nct_id>
  </id_info>
  <brief_title>Treatment of Hypertrophic Scars With Intradermal Botox</brief_title>
  <official_title>Treatment of Hypertrophic Scars With Intradermal Botox</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roy G. Geronemus, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laser and Skin Surgery Center of New York</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label, single center, self-controlled clinical study to
      demonstrate the safety and efficacy of intradermal botulinum toxin in treating hypertrophic
      scarring.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of hypertrophic scars based on the Subject and Observer Scar Assessment Scale</measure>
    <time_frame>change from baseline at 6 months after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertrophic Scar</condition>
  <arm_group>
    <arm_group_label>Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.</description>
    <arm_group_label>Botox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy female and male subjects between the ages 18-75.

          2. Non-Smoker.

          3. Fitzpatrick skin type I-VI.

          4. Desire to improve hypertrophic scarring.

          5. Able and willing to comply with all visit, treatment and evaluation schedules and
             requirements.

          6. Able to understand and provide written Informed Consent.

        Exclusion Criteria:

          1. Pregnant or planning to become pregnant, having given birth less than 3 months ago,
             and/or breast feeding.

          2. Presence of any active systemic or local infections.

          3. Presence of active local skin disease that may alter wound healing.

          4. Known allergy to botulinum toxin.

          5. History of smoking in past 10 years.

          6. History of chronic drug or alcohol abuse.

          7. Inability to understand the protocol or to give informed consent.

          8. History of cosmetic treatments in the area to be treated, including injectable filler
             of any type within the past year; Botox in the treatment area within the past 6
             months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light
             treatment within the past 6 months, dermabrasion or deep peels within the past 6
             months; surgery to the area within the past 6 months.

          9. History of intralesional corticosteroids or any other injectable medication to the
             area within the last 3 months.

         10. History of topical corticosteroids to the area within the past 4 weeks.

         11. History of any musculoskeletal disease or any weakness in the area to be treated.

         12. As per the investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Moreno</last_name>
    <phone>212-686-7306</phone>
    <email>research@laserskinsurgery.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Moreno</last_name>
      <phone>212-686-7306</phone>
      <email>research@laserskinsurgery.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Laser and Skin Surgery Center of New York</investigator_affiliation>
    <investigator_full_name>Roy G. Geronemus, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cicatrix, Hypertrophic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

